In this study, the promoter of the gene coiled-coil domain-containing 67 (CCDC67) was found to be frequently methylated in gastric cancer cell lines and in primary gastric tumors, as examined by restriction landmark genomic scanning. In addition, CCDC67 expression was down-regulated in 72.7% of gastric cancer cell lines tested. In most cases, gene down-regulation was associated with CpG hypermethylation in the CCDC67 promoter. Treatment with 5-aza-2ʹ-deoxycytidine and/or trichostatin A restored CCDC67 expression in down-regulated cell lines. Pyrosequencing analysis of 150 paired primary gastric cancer samples revealed that promoter CpG methylation was increased in 74% of tested tumors compared with paired adjacent normal tissues, and this hypermethylation correlated significantly with down-regulation of CCDC67. CCDC67 protein was localized to the cell membrane by immunocytochemistry. Stable transfection of a CCDC67 gene in one gastric cancer cell line inhibited adhesion-dependent and -independent colony formation, and CCDC67 expression suppressed tumorigenesis in nude mice. We suggest that CCDC67 is a putative tumor suppressor gene that is silenced in gastric cancers by promoter CpG methylation and that it may play an important role in cell signaling and migration related to tumorigenesis.
Introduction
The coiled-coil domain-containing (CCDC) proteins exhibit diverse functions related to their highly versatile folding motif (1) . The coiled-coil motif is found in many proteins, such as skeletal and motor proteins, and is involved in molecular recognition systems and protein refolding (1) . So far, more than 140 genes contain the coiled-coil domain, but their functions are unknown in many cases (http://www. genecards.org/). Previous studies have shown that approximately 40 CCDC genes are associated with diseases, including various metabolic diseases (2) , cancers (3), mitochondrial disease (4), hearing loss (5) , epigenetic disease (6), diabetes (7) and heart disease (8) . Genetic or epigenetic alterations associated with human cancers have been found in several genes, including CCDC19 (NESG1) in nasopharyngeal carcinoma (9) , CCDC62 in prostate cancer (10) , CCDC68 in colorectal cancer (11) and CCDC8 in renal cell carcinoma (12) .
DNA methylation is a key mechanism for inhibiting expression of tumor suppressor genes and other genes involved in tumor progression (13, 14) . This epigenetic change frequently occurs during the early stages of carcinogenesis (15) . Aberrant DNA methylation within a promoter can result in chromatin compaction or down-regulation of gene expression (14, 16) . Recent studies suggest that CpG hypermethylation in the promoters of tumor suppressor genes is an important mechanism of gene silencing that contributes to tumorigenesis (16, 17) . Moreover, DNA methylation has been shown to be a promising biomarker for cancer detection, and aberrant methylation of diverse genes (such as those encoding APC, CACNA2D3, COX2, E-cadherin, hMLH1, MGMT, p16 and TIMP3) has been found in gastric cancer (17, 18) .
Gastric cancer is one of the most common human cancers and is the second-most frequent cause of cancer-related death worldwide (19) . Gastric cancer is predominantly caused by genetic and environmental factors, including activation of oncogenes, inactivation of tumor suppressor genes and infection of Helicobacter pylori (20) . The molecular mechanisms responsible for gastric carcinogenesis remain largely unknown even though genetic and epigenetic alterations of tumor suppressor genes have been studied in a variety of human malignancies, including gastric cancer (17, 18) . To identify DNA methylation markers in gastric cancer, we previously examined global methylation patterns in gastric cancer cell lines and tissues using restriction landmark genomic scanning (RLGS) . From this analysis, we identified aberrant methylation in several genes and suggested roles for these genes in gastric carcinogenesis (21) (22) (23) (24) (25) . Among them, coiled-coil domain-containing 67 (CCDC67) was identified as a novel epigenetic target in gastric cancer.
In this study, we show that down-regulation of CCDC67 in gastric cancer cell lines and tumors is frequently accompanied by hypermethylation of the promoter and that CCDC67 acts as a tumor suppressor by inhibiting growth, colony formation and migration of gastric cancer cells. Our data suggest that CCDC67 is a putative tumor suppressor gene that is regulated epigenetically in gastric cancer.
Materials and methods

Cell lines and tissue samples
The 11 gastric cancer cell lines (SNU-001, -005, -016, -216, -484, -520, -601, -620, -638, -668 and -719) used in this study were supplied by the Korean Cell Line Bank (http://cellbank.snu.ac.kr/index.htm). All cell lines were maintained in RPMI-1640 culture medium (WelGENE Inc., Seoul, Korea) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution (Invitrogen, Carlsbad, CA) in a humidified atmosphere containing 5% CO 2 at 37°C. One hundred and fifty pairs of human gastric tumor and adjacent normal tissues were obtained from the Stomach Cancer Bank at Chungnam National University Hospital, Daejeon, Korea. All samples were obtained with informed consent and their use was approved by the Internal Review Board at Chungnam National University Hospital.
RLGS assays and cloning of a methylated NotI locus
Genomic DNA from gastric cancer cell lines or paired tumor and adjacent normal tissues were isolated by a standard protocol of phenol/chloroform extraction and ethanol precipitation. RLGS was performed using paired tumor and mucosa DNA samples or gastric cancer cell lines as described (26) . Differences between RLGS profiles from the paired samples were examined as described (27) . Once a difference in spot intensity was detected, the spot position was compared with our Standard RLGS profile (28) or the Master RLGS profile (28) to determine the DNA fragment identity and access its sequence.
Real-time reverse-transcription PCR
Total RNA was extracted from gastric cancer cell lines using TRIzol reagent (Invitrogen). Total RNA (1 µg) was reverse-transcribed using iScript reverse transcriptase (Bio-Rad, Hercules, CA) according to the manufacturer's guidelines. Real-time RT-PCR (qRT-PCR) was performed in a CFX96 RealTime PCR Detection System (Bio-Rad). The reverse-transcribed product was amplified in a 15 µl reaction with 2 SYBR Premix EX Taq (Takara, Shiba, Japan) using a CCDC67 primer set (5ʹ-GCAGCTCTGAAATTCCTCGT-3ʹ and 5ʹ-TTGGTTGATCTTGCATCACTG-3ʹ) to yield a 414 bp product. Samples were heated to 95°C for 3 min and then amplified for 40 cycles of 95°C for 30 s, 60°C for 30 s and 72°C for 30 s. All reactions were then incubated at 72°C for 10 min and cooled to 4°C. β-Actin was amplified as a control. Relative quantification of CCDC67 mRNA was analyzed by comparative threshold cycle methods (29) .
Sodium bisulfite modification and bisulfite sequencing
Each genomic DNA (1 µg) was modified by sodium bisulfite using the EZ DNA Methylation Kit (Zymo Research, Orange, CA) according to the manufacturer's instructions. To perform bisulfite sequencing analysis on the 5ʹ-upstream region of CCDC67 (CpG sites from −284 to +194; Figure 1B ), 25 ng bisulfite-modified DNA was amplified in a 20 µl reaction with forward primer 5ʹ-AGGATTTAGAATAGAGGGGGTATTG-3ʹ and reverse primer 5ʹ-AACCTCCCCTCCCAACCT-3ʹ (designed using MethPrimer, http://www. urogene.org/methprimer/index.html) to yield a 554 bp product. PCR products were cloned into pGEM-T Easy Vector (Promega, Southampton, UK), and 10 white colonies were randomly chosen for sequencing.
Pyrosequencing
Seven CpG sites in the 5ʹ-upstream region of CCDC67 were selected for quantitation of methylation (CpG sites from −284 to −250, Figure 1B ). Bisulfitemodified DNA (100 ng) was amplified by PCR in a 25 µl reaction using 2 Dye Mix polymerase (Enzynomics, Daejeon, Korea), forward primer 5ʹ-G GGATTATAAAGAGGAAAGGATTTAG-3ʹ, biotinylated reverse primer 5ʹ-ACCACAAACCCTACCCTATAC-3ʹ to yield a 129 bp product. PCR was performed using an initial melting step of 95°C for 1 min followed by 50 cycles of 95°C for 30 s, 56°C for 40 s and 72°C for 40 s, and a final incubation at 72°C for 5 min. Pyrosequencing was performed according to the manufacturer's guidelines with a sequencing primer (5ʹ-GGGGTATTGGAAGTATAATT-3ʹ) on the PSQ HS 96A System (Biotage AB, Kungsgatan, Sweden).
MethyLight analysis
Five CpG sites before the transcription start site of CCDC67 were selected for MethyLight analysis (CpG sites from 158 to −60, Figure 1B ). According to the previously published MethyLight procedure (30) , bisulfite-modified DNA (100 ng) was amplified in a 30 µl reaction containing 0.3 µM locusspecific PCR primers (forward, 5ʹ-AAAACCCAACTACCTCGTTAATCG-3ʹ; reverse, 5ʹ-CGTTTCGTTAGGTTCGTTTTAAGG-3ʹ), 0. 
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Western blot analysis
For western blotting, 1 mg portions of frozen tumor and adjacent normal tissues were homogenized in 500 µl of a lysis buffer containing 1% Triton X-100, 50 mM Tris and 300 mM NaCl. The lysates were incubated on ice for 15 min with occasional vortexing, and insoluble material was removed by centrifugation. The resultant supernatants were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After electrophoresis, samples were blotted onto polyvinylidene difluoride western blotting membranes (Roche). After 1 h of incubation in a blocking solution of 5% dried milk in TBST buffer (10 mM Tris-base pH 8.0, 150 mM NaCl and 0.1% Tween-20), membranes were incubated with the rabbit polyclonal anti-human CCDC67 antibody (1 µg/ml; Sigma, St Louis, MO) for 24 h at 4°C. After washing in 5% dried milk in TBST buffer, membranes were incubated with goat antirabbit IgG-horseradish peroxidase (Santa Cruz Biotechnology), and the blots were visualized by the enhanced chemiluminescence detection method using a WEST-ZOL ® Plus kit (iNtRON Biotechnology Inc., Korea).
Restoration of CCDC67 expression by treatment with 5-aza-2ʹ-deoxycytidine
Gastric cancer cell lines (SNU-601 and SNU-638) were seeded in 35 mm dishes at a density of 1  10 5 cells/dish 1 day before drug treatment. Cells were treated with 10 µM 5-aza-2ʹ-deoxycytidine (5-aza-dC; Sigma) every 24 h for 3 days and then harvested. Another culture of cells was treated with 0.5 µM trichostatin A (TSA, Sigma) for 1 day. To test the combined effect of 5-aza-dC and TSA, cells were treated with 10 µM 5-aza-dC every 24 h for 3 days and then with 0.5 µM TSA for 1 day. DNA was prepared and tested for reversion of CCDC67 methylation by pyrosequencing. Total RNA was prepared and tested for restoration of CCDC67 expression by real-time PCR.
Cloning of CCDC67 and construction of a stable cell line
To prepare a CCDC67-expressing cell line, the CCDC67 coding sequence was first amplified from a cDNA prepared from a normal gastric tissue by PCR using primers EcoRI-CCDC67-F 5ʹ-GAATTCATGGAGAACCAAGCCCAT AAT-3ʹ and NotI-CCDC67-R 5ʹ-TCCAAGCTAAAACAAAATAGACACATA TGGCGGCCGC-3ʹ and cloned into the pGEM-T Easy vector. After sequence confirmation, the full-length CCDC67 cDNA was subcloned into pLPCX (Clontech, Mountain View, CA) at the EcoRI and NotI sites. A retroviral supernatant containing CCDC67 was obtained from HEK293T cells transfected with the pLPCX-CCDC67 plasmid. The CCDC67 virus was infected into SNU-638 cells, and stable CCDC67-expressing cells (SNU-638/CCDC67) were selected in RPMI-1640 medium containing puromycin (5µg/ml). Overexpression of CCDC67 was confirmed by RT-PCR and western blot analysis.
Subcellular localization of CCDC67
The full-length CCDC67 cDNA was subcloned into pEGFP-N3 (Clontech) at the HindIII and EcoRI sites to generate a C-terminal green fluorescent protein (GFP) fusion protein. SNU-638 cells were seeded on 25 mm coverslips and transfected with pEGFP-N3-CCDC67 or control vectors using Lipofectamine Plus (Invitrogen). At 2 days post-transfection, cells were observed under a Zeiss LSM 510 confocal laser scanning microscope (Carl Zeiss, Thornwood, NY).
Immunocytochemistry assay
For intracellular localization of CCDC67, SNU-216 cells were seeded in to the channel of an ibiTreat µ-Slide VI ibiTreat (lbidi, Munich, Germany) at a density of 3-7  10 5 per well. The cells were washed with phosphate-buffered saline (PBS), fixed for 20 min in 4% paraformaldehyde, washed, permeabilized with 0.3% Triton X-100 in PBS for 20 min, washed and blocked with 5% bovine serum albumin in PBS for 1 h. Each channel was then incubated with a primary anti-CCDC67 antibody (1:50) at 4°C overnight, washed, incubated with fluorescein isothiocyanate (FITC)-or tetramethyl rhodamine isothiocyanate-labeled second antibody (1:100) for 1 h at room temperature, washed, counterstained with 4ʹ,6-diamidino-2-phenylindole staining for 10 min at room temperature, washed and finally observed with a confocal microscope.
Proliferation and colony-forming assays
For the proliferation assay, SNU-638/CCDC67 cells were seeded at 5  10 3 cells/well in a 96 well plate and incubated at 37°C for 4 days. Cell Counting Kit-8 reagent (10 µl; Dojindo, Tokyo, Japan) was added to the cells, the cells were then incubated for 3 h, and absorbance was measured at 450 nm using a spectrophotometer (Bio-Rad). For the colony forming assay, SNU-638/CCDC67 cells were plated at 2  10 3 cells/well in a six-well plate, incubated for 2 weeks in RPMI-1640 containing puromycin (1 µg/ml), and stained with crystal violet. For the colony-formation assay in a soft agar, cells (0.5  10 3 cells/well) were suspended in RPMI-1640 containing 0.4% agarose, 10% FBS, and puromycin (1 µg/ml) and layered on RPMI-1640 containing 0.8% agarose, 10% FBS and puromycin (1 µg/ml) in a six-well plate. Colonies were photographed and counted after 3 weeks of incubation at 37°C. All assays were performed in triplicate.
Transwell migration assay
Transwell migration assays were performed in a 24 well transwell chamber (Corning, NY) fitted with a polycarbonate membrane (8 mm pore size). SNU-638/CCDC67 cells were washed twice with serum-free medium, resuspended in 100 µl (2  10 4 cells/well) serum-free medium and added to the upper chamber. The lower chamber was filled with RPMI-1640 containing 10% FBS. After 30 h, migrated cells were fixed for 20 min with methanol and stained with 0.25% crystal violet, 10% formaldehyde and 80% methanol for 6 h, and then washed with ddH 2 O to remove non-adherent cells. Ten random fields were captured under 100 magnification for each membrane, and migrated cells were counted.
In vivo tumorigenicity assay
Four-week-old male BALB/c nude mice (Japan SLC, Inc.) were housed in accordance with the guidelines and under approval of the Institutional Review Committee for the Animal Care and Use, Korea Research Institute of Bioscience and Biotechnology. SNU-638/CCDC67 cells and vector control-transfected cells (~6  10 6 ) were collected by centrifugation, washed twice in PBS, and inoculated subcutaneously into the right flank region of nude mice (eight mice per cell line). Tumor nodules were measured every 7 days with a caliper. Mice were sacrificed at the end of 46 days, and the tumor growth rate and tumor inhibiting rate were calculated.
Statistical analysis
A paired t-test was used to test differences in mRNA expression or promoter methylation between paired sets of primary gastric tumors and adjacent normal tissues. Values were expressed as the mean ± standard deviation of the mean; P < 0.05 was considered significant.
Results
Analysis of CpG methylation of the CCDC67 promoter in gastric cancer by RLGS analysis
We performed RLGS to detect aberrant methylation of genomic DNA in gastric cancer cell lines and tumor tissues compared with normal gastric mucosa tissues. We found a DNA spot with frequently decreased intensity in primary tumors. Figure 1A shows representative changes in spot intensity in two primary gastric cancers (patients 0316 and 053, middle panels), with no changes in their paired normal mucosa tissues (upper panels). This spot was absent in the SNU-001 gastric cancer cell line but present at low intensity in the SNU-216 cell line (bottom panels). This spot corresponded to spot number 3B79 (GenBank accession no. CG464599), which we previously identified by mixing RLGS gels with NotI-linked clones (27) . The sequence of clone 3B79 was matched to the NotI/EcoRV fragment covering the 5ʹ-upstream region and exon 1 of CCDC67 on human chromosome 11q21. The DNA sequence of spot 3B79 also overlapped with a CpG island in the CCDC67 promoter ( Figure 1B) , suggesting that the decreased intensity of 3B79 may be associated with CpG island methylation in the CCDC67 promoter in gastric cancer.
Reduced CCDC67 expression correlates with promoter CpG hypermethylation in gastric cancer cell lines
To elucidate a potential correlation between promoter methylation and CCDC67 down-regulation in gastric cancer, we first examined CCDC67 mRNA expression in 11 gastric cancer cell lines using RT-PCR. CCDC67 expression was silenced or significantly downregulated in nine gastric cancer cell lines (81%, Figure 1C ), including SNU-001, which had decreased 3B79 intensity in the RLGS profile. We next assessed the methylation status of 69 CpG sites around the transcription initiation site of CCDC67 by bisulfite sequencing (bottom of Figure 1B ). Heavy CpG methylation (>90% of 69 CpG sites) was found in seven gastric cancer cell lines (SNU-001, -005, -520, -601, -620, -638 and -719; Figure 1D ), all of which had significantly down-regulated CCDC67 expression ( Figure 1C) . Three gastric cancer cell lines that had rare CpG methylation expressed CCDC67 to some extent (SNU-016, -216 and -668). Only SNU-484 had no CCDC67 expression and rare CpG methylation exceptionally. To see if the loss of expression was caused by epigenetic inhibition at the CCDC67 promoter, we treated SNU-601 and SNU-638 cells, which had down-regulated CCDC67 expression and promoter CpG hypermethylation, with 5-aza-dC and/or TSA and measured CCDC67 mRNA expression by qRT-PCR. The level of CCDC67 expression was significantly restored in all 5-aza-dC-treated and co-treated cells compared with untreated control cells (P < 0.01, Figure 1E ). CCDC67 expression was also restored somewhat in TSA-treated cells, but the difference was not statistically significant (P = 0.053 in SNU-601 and P = 0.342 in SNU-638, Figure 1E ). These results suggested that CCDC67 expression in these gastric cancer cells was regulated by an epigenetic mechanism such as DNA methylation or histone modification.
CCDC67 down-regulation correlates with promoter CpG hypermethylation in primary gastric tumors
We next examined four paired primary gastric tumors and adjacent mucosa tissues for CCDC67 mRNA or protein expression (RT-PCR or western blot analysis) and methylation status of promoter CpG sites (bisulfite sequencing analysis). CCDC67 expression was significantly reduced in all four tumors compared with their paired normal mucosa tissues (upper panel of Figure 2A ) and the protein level was also reduced in three tumors except one (#063) (bottom panel of Figure  2A ). In addition, the promoter CpG sites were more heavily methylated in gastric tumors compared with the normal tissues ( Figure 2B) , showing that hypermethylation corresponded to decreased CCDC67 expression in gastric tumors. Moreover, we found a positive CCDC67 staining in normal gland cells, but not in diffuse-type gastric tumor using immunohistochemistry on paraffin-embedded sections (Supplementary Figure 2A , available at Carcinogenesis Online). We also found CCDC67 expression in intestinal metaplasia of another clinical sample (Supplementary Figure 2B , available at Carcinogenesis Online), suggesting that CCDC67 is still expressed in intestinal metaplasia as well as in normal gland cells, but not in gastric tumors, though further analysis from more clinical samples is needed.
To further elucidate the status of promoter CpG methylation during gastric carcinogenesis, we performed pyrosequencing analysis on eight CpG sites in the CCDC67 promoter (−284 to −250, Figure 1B ) in 150 paired gastric tumors and adjacent normal tissues. The mean percent methylation was 12.2%, 12.0%, 10.5%, 12.2%, 7.8%, 14.1%, 8.4% and 10.3% for each of the eight CpG sites from 150 normal tissues. The overall mean percent methylation, calculated from the average of these individual values, was 10.9%. In contrast, the overall mean percent methylation from tumor tissues was 18.3%, revealing a significant difference compared with normal tissues (P < 0.0001; Figure 2C ). CCDC67 hypermethylation was analyzed in detail based on age, gender and three clinicopathological categories, including tumor depth (early versus advanced gastric cancer), staging and Lauren's classification, but no significant differences were observed (Supplementary Table 1 , available at Carcinogenesis Online). We also performed qRT-PCR in 80 paired gastric tumors and adjacent normal tissues and found that the mean CCDC67 expression was significantly reduced in tumors (P < 0.001; Figure 2D ). The majority of tumors (58/80 or 72.5%) expressed CCC67 at a level lower than their respective paired normal tissues, and 45/80 (56.3%) had a decrease of >2-fold.
To see if methylation of the CCDC67 promoter was associated with CCDC67 expression in the clinical samples, we calculated Pearson's correlation coefficient between relative expression and methylation and inferred its significance by t-test. For 58 pairs of tumor and normal samples, we used the log 2-transformed ratio between tumor and 
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normal samples as the relative expression and defined the methylation change as the difference in methylation between tumor and normal samples. We found a significant negative correlation between relative expression and methylation change (r = −0.2705, P < 0.05, Figure 2E ), indicating that decreased CCDC67 expression was associated with increased methylation in the clinical samples. However, we found no correlation between patient age and methylation or expression of CCDC67 (data not shown). These results indicated that abnormal methylation of CCDC67 is a typical cancer-specific (type C), but not age-related (type A), marker (31) .
To examine other possible CpG sites associated with CCDC67 silencing, we analyzed the methylation status on additional five CpG sites (−158 to −60) before the transcription start site of the gene using MethyLight analysis (bottom of Figure 1B) . The analysis was performed in another 99 paired gastric tumors and adjacent normal tissues. As a result, the methylation status in tumor tissues was significantly higher than in the non-tumor (P < 0.001; Supplementary  Figure 1 , available at Carcinogenesis Online). CCDC67 hypermethylation was also analyzed in detail based on several clinicopathological categories as the previous analysis on the CCDC67 promoter (−284 to −250), but no significant differences were also observed (data not shown), suggesting that two CpG regions (−158 to −60) and (−284 to −250) tested in this study were similar to each other in terms of the association with gene silencing or clinical parameters..
CCDC67 protein localizes to the plasma membrane
We established stably transfected CCDC67-expressing SNU-638 cell lines using a GFP-tagged CCDC67 expression vector, because CCDC67 is hypermethylated and transcriptionally silenced in SNU-638 cells ( Figure 1C) . The intracellular localization of CCDC67 was investigated. GFP-CCDC67 expression was confirmed by western blotting using mouse anti-GFP and rabbit anti-CCDC67, both conjugated with FITC ( Figure 3A) . CCDC67 signals were then analyzed by confocal microscopy after 48 h of transfection. Figure 3B shows that GFP-CCDC67 localized to the cell membrane of transfected SNU-638 cells. Localization to the plasma membrane was confirmed by immunocytochemistry using rabbit anti-CCDC67 in SNU-216 cells ( Figure 3C ), which endogenously express CCDC67 ( Figure 1C ). These observations corresponded well to the prior description of CCDC67 as a membrane protein (http://www.genecards.org/).
CCDC67 suppresses cell proliferation, colony formation and migration in vitro
CCDC67 expression in three SNU-638/CCDC67 cell lines was confirmed by RT-PCR and western blot analysis ( Figure 4A ). We selected the CCDC67#3 line for subsequent experiments based on its stable expression of CCDC67 mRNA and protein. Figure 4B shows the result of a cell proliferation assay indicating that the growth of CCDC67#3 cells was significantly inhibited compared with that of cells transfected with control vector. Colony-formation assays also showed that CCDC67 overexpression significantly inhibited colony formation in both a monolayer assay (P < 0.01, Figure 4C ) and a soft-agar assay (P < 0.01, Figure 4D ). In addition, a transwell migration assay showed that the migration of CCDC67#3 was significantly decreased compared with that of empty vector control cells (P < 0.001, Figure 4E ). These results suggested that CCDC67 has tumor suppressor activity and is a negative regulator of tumor growth in vitro.
CCDC67 has tumor suppressor activity in vivo Finally, we examined the effect of CCDC67 overexpression in a tumorigenesis assay in nude mice. Nude mice were injected with stably transfected CCDC67#03 cells or empty vector-transfected cells. Mice were sacrificed 46 days after injection, and their tumors were dissected and weighed. The control cells formed rapidly growing tumors ( Figure 5 ), whereas the CCDC67#03 cells formed tumors that were much smaller in both volume and weight. This suggested that CCDC67 is a tumor suppressor gene that is a negative regulator of tumor growth both in vitro and in vivo.
Discussion
In this study, we report for the first time that expression of CCDC67 is repressed in gastric cancer cells by an epigenetic mechanism and that its normal expression results in tumor suppressor activity both in vitro and in vivo. Our results suggest that CCDC67 is a new tumor suppressor gene in gastric cancer. CCDC67 expression was repressed in most of the gastric cancer cell lines (81.8% with 9/11) and gastric tumor tissues (72.5% with 58/80) tested. Restoration of CCDC67 expression in gastric cell lines strongly inhibited cell growth both in monolayer and soft-agar assays. Finally, expression of CCDC67 in xenografted mice greatly reduced tumor growth.
Our previous studies showed that the promoters of POPDC3, LRRC3B, DCBLD2, PKD1 and LIMS2 are differentially methylated in gastric cancers as seen by RLGS and that all of these genes have potential tumor suppressor activity (21) (22) (23) (24) (25) . Thus, our results demonstrate that RLGS is a useful approach for identifying differen- promoter was intensely methylated and CCDC67 mRNA expression was significantly reduced) were transfected with a CCDC67-GFP expression vector. Western blotting was performed with anti-GFP and anti-CCDC67. α-Tubulin was used as a control. (B) Subcellular localization of CCDC67-GFP in SNU-638 cells. The CCDC67-GFP fusion protein was labeled in transfected SNU-638 cells using anti-GFP and an FITC-conjugated secondary antibody and detected by excitation with a 488 nm line from an argon laser using confocal laser scanning microscopy. Arrows indicate CCDC67 localized in the plasma membrane (original magnification 400). (C) Subcellular localization of CCDC67 in SNU-216 cells using anti-CCDC67 and an FITC-conjugated secondary antibody. As shown in Figure  1C and D, the CCDC67 promoter was hypomethylated and CCDC67 mRNA was highly expressed in SNU-216 cells. Arrows indicate CCDC67 protein in the plasma membrane of SNU-216 cells (left panel). 4ʹ,6-Diamidino-2-phenylindole (blue, B and C) and anti-actin (red, C) staining are also shown. Anti-actin was stained as a cytoskeletal marker in contrast to CCDC67 which is localized to membrane. tially methylated DNA in human cancers, including gastric cancer, despite the fact that its capability for genome screening is below the level of the recent array-based technologies (32) or next-generation sequencing-based methylome analysis (33) . The 3B79 spot that was frequently methylated in gastric cancer cell lines and gastric tumors in this study corresponded to spot 16, which was also frequently methylated in hepatocellular carcinoma (34) . This suggests that silencing of CCDC67 by promoter CpG methylation may also be associated with hepatocellular carcinoma development.
One known function of the coiled-coil motif is the recognition of other molecules (2) . For instance, coiled-coil domains are involved in molecular recognition systems for SNARE proteins (35) , which mediate cell membrane fusion. Tetranectin has both a carbohydrate-recognition domain and a coiled-coil domain, and their relative orientation is important for binding to carbohydrates (36) . To date, more than 140 genes are known to contain a coiled-coil domain, but their functions in many cases are unknown. A few of these genes are associated with cancer (9-11,32), but little is known about CCDC67 function and the localization of its protein product. The GENT database shows that CCDC67 mRNA is down-regulated in cancers of the ovary, lung, head and neck, cervix, breast, brain, stomach and testis compared with corresponding normal tissues ( Figure 6 ). This suggests that CCDC67 may be associated with various types of cancer as well as gastric cancer, as shown in this study.
The NCBI database shows that CCDC67 encodes a 604 amino acid protein containing a coiled-coil domain. Our present results show that CCDC67 protein localized to the cell membrane in SNU-638 cells expressing ectopic GFP-CCDC67 and in SNU-216 expressing endogenous CCDC67, supporting the GeneCards database notation that CCDC67 is a membrane protein (http://www.genecards.org/). These results suggest that CCDC67 may be associated with cell signaling related to cancer formation, as shown previously (9, 32) . According to NCBI HomoloGene (18760), the amino acid sequence of human CCDC67 is 98.7% identical with chimpanzee (Pan troglodytes), 88.8% with wolf (Canis lupus) and 81.9% with rat (Rattus norvegicus), indicating that CCDC67 has been highly conserved throughout evolution of Amniota.
One of the major mechanisms of tumor progression is inactivation of tumor suppressor genes, which is induced by diverse mechanisms After selection with puromycin for 3 weeks, CCDC67-or empty vector-expressing mixed populations were selected and then mRNA and protein expression of these cell lines were assessed by RT-PCR and western blotting with anti-CCDC67, respectively. β-Actin and α-tubulin were used as controls, respectively. (B) Cell proliferation assay. CCDC67#3 cells in panel A were cultured for 1-4 days, and cell growth was measured using a CCK-8 kit. Proliferation was significantly decreased in CCDC67#3 cells compared with CTL (P < 0.05). (C) Adhesion-dependent colony-formation assay in monolayer culture. CCDC67#3 and CTL cells were plated in six-well plates at 3000 cells/well. After 2 weeks of incubation, cells were stained with crystal violet. (D) Adhesion-independent colony-formation assay in soft agar. CCDC67#3 and control cells were plated in top agarose (0.3%) over bottom agarose (0.6%). Colonies were counted after 3 weeks of incubation. (E) Cell migration assay. CCDC67#3 and CTL cells were seeded in fibronectin-coated transwells and allowed to migrate for 24 h. In C-E, representative images are shown and graphs represent mean colony number or migrated cell number from three independent experiments (bars, standard deviation).
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such as chromosomal deletion, loss-of-function mutations in the coding region or by epigenetic alterations in the form of DNA methylation of promoter regions (37, 38) . Recently, many tumor suppressor genes and DNA repair genes (e.g. p16, MGMT, VHL, MLH1 and BRCA1) were shown to be inactivated by methylation in tumors (39) . In this study, ectopic CCDC67 expression in a gastric cancer cell line (SNU-638) in which CCDC67 was silenced by promoter hypermethylation significantly suppressed cell proliferation, colony formation and cell migration. Our present results show that promoter CpG hypermethylation is a major mechanism for inactivation of CCDC67 as a tumor suppressor in gastric cancer cell lines and gastric tumors.
Epigenetics is the study of heritable changes in gene expression caused by non-genetic mechanisms such as reversible DNA methylation and/or histone acetylation, both of which serve to suppress gene expression. Our pyrosequencing and RT-PCR analysis data show that CpG methylation of the CCDC67 promoter correlates negatively with CCDC67 expression in 10 gastric cancer cell lines, indicating that the regulation of CCDC67 expression depends on an epigenetic mechanism in these cells. In contrast, no CCDC67 expression was detected in SNU-484 cells, although the promoter CpG sites were almost entirely methylation free. Although this result is contrary to our expectations based on an epigenetic regulatory model, we previously reported a similar result with another epigenetic target (6) . In that case, LIMS2 was highly expressed in SNU-484 cells despite hypermethylation of its promoter. It is plausible that CCDC67 has reduced promoter function in SNU-484 cells owing to abnormal chromatin structure even though the promoter CpG sites lack methylation. Further molecular studies are needed to elucidate this exceptional case in epigenetic regulation.
Taken together, we propose that CCDC67 is a novel tumor suppressor gene associated with gastric carcinogenesis, that it affects cell proliferation, and that its expression is mainly regulated by promoter methylation. Further studies will address the potential use of CCDC67 methylation as a molecular biomarker for assessing the risk of gastric cancer development or as a therapeutic target for improving the treatment of gastric cancer patients.
Supplementary material
Supplementary Table 1 and Figures 1 and 2 can be found at http:// carcin.oxfordjournals.org/.
